The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models-Reference-Cited by-同舟云学术

The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models

Published:2019-02-07 Issue:8 Volume:104 Page:1633-1639
ISSN:0390-6078
Container-title:Haematologica
language:en
Short-container-title:Haematologica

Author:

Hicks Stuart W.,Tarantelli Chiara,Wilhem Alan,Gaudio Eugenio,Li Min,Arribas Alberto J.,Spriano Filippo,Bordone Roberta,Cascione Luciano,Lai Katharine C.,Qiu Qifeng,Taborelli Monica,Rossi Davide,Stussi Georg,Zucca Emanuele,Stathis Anastasios,Sloss Callum M.,Bertoni Francesco

Publisher

Ferrata Storti Foundation (Haematologica)

Subject

Hematology

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting CD25+ lymphoma cells with the antibody–drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agents;British Journal of Haematology;2024-07-30

2. Applications of Nanotechnology in Converging the Biomarker Science for Advancement in Cancer Detection and Treatment;Handbook of Oncobiology: From Basic to Clinical Sciences;2024

3. ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms;Molecular Cancer Therapeutics;2023-12-05

4. PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine;2023-11-16

5. How to integrate CD19 specific chimeric antigen receptor T cells with other CD19 targeting agents in diffuse large B‐cell lymphoma?;Hematological Oncology;2023-11-08